Additional evidence for a pathologic CaV1.3 up-regulation is based on pharmacologic studies with the cyclooxygenase-2 inhibitor, celecoxib, which exerts chemopreventive effects against multiple cancers, including prostate cancer [89]. The gene discussed is CACNA1D; the disease is Familial prostate cancer.